Literature DB >> 24898718

The pharmacologic management of delirium in children and adolescents.

Susan Beckwitt Turkel1, Alan Hanft.   

Abstract

Delirium is a serious and common problem in severely medically ill patients of all ages. It has been less addressed in children and adolescents. Treatment of delirium is predicated on addressing its underlying cause. The management of its symptoms depends on the off-label use of antipsychotics, while avoiding agents that precipitate or worsen delirium. Olanzapine, quetiapine, and risperidone are presently considered first-line drugs, usually replacing haloperidol. Other agents have shown promise, including melatonin to address the sleep disturbance characteristic of delirium, and dexmedetomidine, an α2-agonist, that may facilitate lower doses of benzodiazepines and opioids that may worsen delirium.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24898718     DOI: 10.1007/s40272-014-0078-0

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  93 in total

1.  Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses.

Authors:  I Gaertner; K Altendorf; A Batra; H J Gaertner
Journal:  J Clin Psychopharmacol       Date:  2001-04       Impact factor: 3.153

2.  Delirium in hospitalized older patients.

Authors:  C E Schwartz
Journal:  N Engl J Med       Date:  1999-07-29       Impact factor: 91.245

3.  Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium.

Authors:  L Tune; S Carr; E Hoag; T Cooper
Journal:  Am J Psychiatry       Date:  1992-10       Impact factor: 18.112

Review 4.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.

Authors:  Christoph U Correll
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-01       Impact factor: 8.829

5.  Delirium as a predictor of long-term cognitive impairment in survivors of critical illness.

Authors:  Timothy D Girard; James C Jackson; Pratik P Pandharipande; Brenda T Pun; Jennifer L Thompson; Ayumi K Shintani; Sharon M Gordon; Angelo E Canonico; Robert S Dittus; Gordon R Bernard; E Wesley Ely
Journal:  Crit Care Med       Date:  2010-07       Impact factor: 7.598

Review 6.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

Review 7.  Delirium: guidelines for general hospitals.

Authors:  Laurent Michaud; Christophe Büla; Alexandre Berney; Vincent Camus; Rachel Voellinger; Friedrich Stiefel; Bernard Burnand
Journal:  J Psychosom Res       Date:  2007-03       Impact factor: 3.006

Review 8.  Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Authors:  Silvio Caccia
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

Review 9.  New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications.

Authors:  Lorenzo Leggio; George A Kenna; Robert M Swift
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-10-04       Impact factor: 5.067

10.  A comparison of the phenomenology of pediatric, adult, and geriatric delirium.

Authors:  Albert F G Leentjens; Jan N M Schieveld; Maeve Leonard; Richel Lousberg; Frans R J Verhey; David J Meagher
Journal:  J Psychosom Res       Date:  2008-02       Impact factor: 3.006

View more
  12 in total

1.  Management of Hyperactive Delirium in the Pediatric Intensive Care Unit: Case Series of Three Young Children.

Authors:  Anna O Jesus; Lotte Jones; Rebecca Linares; Marcia L Buck; Deborah U Frank
Journal:  J Pediatr Intensive Care       Date:  2019-11-21

Review 2.  Pediatric Delirium: Evaluation, Management, and Special Considerations.

Authors:  Nasuh Malas; Khyati Brahmbhatt; Cristin McDermott; Allanceson Smith; Roberto Ortiz-Aguayo; Susan Turkel
Journal:  Curr Psychiatry Rep       Date:  2017-08-12       Impact factor: 5.285

3.  Evaluation of the Safety of Quetiapine in Treating Delirium in Critically Ill Children: A Retrospective Review.

Authors:  Christine Joyce; Robert Witcher; Elizabeth Herrup; Savneet Kaur; Elena Mendez-Rico; Gabrielle Silver; Bruce M Greenwald; Chani Traube
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-10-15       Impact factor: 2.576

4.  Evaluation of Pediatric Delirium Awareness and Management in Pediatric Intensive Care Units in Turkey.

Authors:  Capan Konca; Ayse Berna Anil; Emine Pinar Küllüoglu; Doga Luleyap; Murat Anil; Mehmet Tekin
Journal:  J Pediatr Intensive Care       Date:  2020-12-15

5.  Opioid use is Associated with ICU Delirium in Mechanically Ventilated Children.

Authors:  Neha Gupta; Allison Woolley; Saurabh Talathi; Ganisher Davlyatov; Candice Colston; Leslie Hayes
Journal:  J Crit Care Med (Targu Mures)       Date:  2020-08-11

Review 6.  Pediatric Delirium: Recognition, Management, and Outcome.

Authors:  Susan Beckwitt Turkel
Journal:  Curr Psychiatry Rep       Date:  2017-11-07       Impact factor: 5.285

7.  Impact of Two Educational Modules on Practitioner Knowledge of Pediatric Delirium.

Authors:  Allyson D Gabbard; Leslie K Patatanian
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jul-Aug

8.  The stability of quetiapine oral suspension compounded from commercially available tablets.

Authors:  Jennie Tran; Melissa A Gervase; Jason Evans; Rebecca Deville; Xiaowei Dong
Journal:  PLoS One       Date:  2021-08-10       Impact factor: 3.240

Review 9.  Current State of Analgesia and Sedation in the Pediatric Intensive Care Unit.

Authors:  Chinyere Egbuta; Keira P Mason
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

Review 10.  Pediatric Consultation-Liaison Psychiatry: An Update and Review.

Authors:  Jessica E Becker; Joshua R Smith; Eric P Hazen
Journal:  Psychosomatics       Date:  2020-04-25       Impact factor: 2.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.